MATH, a novel measure of intratumor genetic heteroge classes of head and neck squamous cell carcinoma

Oral Oncology

49, 211-215

DOI: 10.1016/j.oraloncology.2012.09.007

Citation Report

#	Article	IF	Citations
1	Gene Expression Analysis As a Tool in Early-Stage Oral Cancer Management. Journal of Clinical Oncology, 2012, 30, 4053-4055.	0.8	7
2	High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer, 2013, 119, 3034-3042.	2.0	180
3	Impact of Human Papillomavirus on Oropharyngeal Cancer Biology and Response to Therapy. Otolaryngologic Clinics of North America, 2013, 46, 521-543.	0.5	49
4	Tumor Evolution and Intratumor Heterogeneity of an Oropharyngeal Squamous Cell Carcinoma Revealed by Whole-Genome Sequencing. Neoplasia, 2013, 15, 1371-IN7.	2.3	78
5	HPV: Sex, cancer and a virus. Nature, 2013, 503, 330-332.	13.7	32
6	Epithelial-mesenchymal transition in human papillomavirus-positive and -negative oropharyngeal squamous cell carcinoma. Oncology Reports, 2014, 32, 2673-2679.	1.2	15
7	Somatic mutations in arachidonic acid metabolism pathway genes enhance oral cancer post-treatment disease-free survival. Nature Communications, 2014, 5, 5835.	5.8	31
8	Next generation sequencing and its application in deciphering head and neck cancer. Oral Oncology, 2014, 50, 247-253.	0.8	26
9	Harnessing Massively Parallel Sequencing in Personalized Head and Neck Oncology. Journal of Dental Research, 2014, 93, 437-444.	2.5	15
10	Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. Genes and Diseases, 2014, 1, 75-86.	1.5	78
11	Use of next generation sequencing in head and neck squamous cell carcinomas: A review. Oral Oncology, 2014, 50, 1035-1040.	0.8	21
12	Treatment De-intensification in HPV-Associated Oropharyngeal Cancer: Evidence, Controversies, and Strategies. Current Otorhinolaryngology Reports, 2015, 3, 47-55.	0.2	0
13	Upregulation of osteoprotegerin expression correlates with bone invasion and predicts poor clinical outcome in oral cancer. Oral Oncology, 2015, 51, 247-253.	0.8	18
14	Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution. Cancer Cell, 2015, 27, 15-26.	7.7	923
15	Breast Cancer Genomics From Microarrays to Massively Parallel Sequencing: Paradigms and New Insights. Journal of the National Cancer Institute, 2015, 107, .	3.0	80
16	Intra-tumor Genetic Heterogeneity and Mortality in Head and Neck Cancer: Analysis of Data from The Cancer Genome Atlas. PLoS Medicine, 2015, 12, e1001786.	3.9	244
17	Open Access to Large Scale Datasets Is Needed to Translate Knowledge of Cancer Heterogeneity into Better Patient Outcomes. PLoS Medicine, 2015, 12, e1001794.	3.9	14
18	Capturing cancerâ€™s complexity. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 4509-4511.	3.3	19

#	Article	IF	Citations
19	Mutant Allele Tumor Heterogeneity (MATH) and Head and Neck Squamous Cell Carcinoma. Head and Neck Pathology, 2015, 9, 1-5.	1.3	43
20	Molecular Aspects of Head and Neck Cancer Therapy. Hematology/Oncology Clinics of North America, 2015, 29, 971-992.	0.9	45
21	Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. Journal of Clinical Oncology, 2015, 33, 3621-3627.	0.8	172
22	Features and prognostic utility of biopsy in oral squamous cell carcinoma. Head and Neck, 2016, 38, E1857-62.	0.9	9
24	Immune signaling-based Cascade Propagation approach re-stratifies HNSCC patients. Methods, 2016, 111, 72-79.	1.9	5
25	Intraâ€tumor heterogeneity in head and neck cancer and its clinical implications. World Journal of Otorhinolaryngology - Head and Neck Surgery, 2016, 2, 60-67.	0.7	48
26	Patient-derived tumour xenografts for breast cancer drug discovery. Endocrine-Related Cancer, 2016, 23, T259-T270.	1.6	13
27	Genomic insights into head and neck cancer. Cancers of the Head & Neck, 2016, 1, .	6.2	65
28	Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer. Gastroenterology, 2016, 151, 961-972.	0.6	41
29	A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell, 2016, 167, 260-274.e22.	13.5	376
30	The effect of human papillomavirus on DNA repair in head and neck squamous cell carcinoma. Oral Oncology, 2016, 61, 27-30.	0.8	8
31	The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. Blood, 2016, 127, 1870-1880.	0.6	58
32	The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. Nature Communications, 2016, 7, 11479.	5.8	1,221
33	Past and future impact of nextâ€generation sequencing in head and neck cancer. Head and Neck, 2016, 38, E2395-402.	0.9	6
34	Multiregion Whole-Exome Sequencing Uncovers the Genetic Evolution and Mutational Heterogeneity of Early-Stage Metastatic Melanoma. Cancer Research, 2016, 76, 4765-4774.	0.4	86
35	Clinical and molecular relevance of mutant-allele tumor heterogeneity in breast cancer. Breast Cancer Research and Treatment, 2017, 162, 39-48.	1.1	47
36	Mutant-Allele Tumor Heterogeneity Scores Correlate With Risk of Metastases in ColonÂCancer. Clinical Colorectal Cancer, 2017, 16, e165-e170.	1.0	39
37	Microfluidic continuum sorting of sub-populations of tumor cells via surface antibody expression levels. Lab on A Chip, 2017, 17, 1349-1358.	3.1	26

#	Article	IF	Citations
38	A population genetics perspective on the determinants of intra-tumor heterogeneity. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1867, 109-126.	3.3	37
39	Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer. Cancer Research, 2017, 77, 3317-3324.	0.4	117
40	Gender-related prognostic value and genomic pattern of intra-tumor heterogeneity in colorectal cancer. Carcinogenesis, 2017, 38, 837-846.	1.3	30
41	Subclonal diversity arises early even in small colorectal tumours and contributes to differential growth fates. Gut, 2017, 66, 2132-2140.	6.1	39
42	Tumor Evolution as a Therapeutic Target. Cancer Discovery, 2017, 7, 805-817.	7.7	158
43	Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer. JAMA Oncology, 2017, 3, 1707.	3.4	129
44	An oral cavity squamous cell carcinoma quantitative histomorphometric-based image classifier of nuclear morphology can risk stratify patients for disease-specific survival. Modern Pathology, 2017, 30, 1655-1665.	2.9	60
45	A seven-gene prognostic signature for rapid determination of head and neck squamous cell carcinoma survival. Oncology Reports, 2017, 38, 3403-3411.	1.2	29
46	Quantification of within-sample genetic heterogeneity from SNP-array data. Scientific Reports, 2017, 7, 3248.	1.6	6
47	The challenges of tumor genetic diversity. Cancer, 2017, 123, 917-927.	2.0	67
48	Clonal cooperativity in heterogenous cancers. Seminars in Cell and Developmental Biology, 2017, 64, 79-89.	2.3	53
49	Mutantâ€'allele fraction heterogeneity is associated with nonâ€'small cell lung cancer patient survival. Oncology Letters, 2017, 15, 795-802.	0.8	11
50	The subclonal structure and genomic evolution of oral squamous cell carcinoma revealed by ultra-deep sequencing. Oncotarget, 2017, 8, 16571-16580.	0.8	25
51	The Molecular Biology of Head and Neck Cancer. , 2017, , 243-256.		1
52	The molecular landscape of head and neck cancer. Nature Reviews Cancer, 2018, 18, 269-282.	12.8	897
53	Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. Seminars in Cancer Biology, 2018, 52, 228-240.	4.3	314
54	Patient-derived conditionally reprogrammed cells maintain intra-tumor genetic heterogeneity. Scientific Reports, 2018, 8, 4097.	1.6	34
55	Big Bang Tumor Growth and Clonal Evolution. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a028381.	2.9	38

#	Article	IF	Citations
56	High-dimension single-cell analysis applied to cancer. Molecular Aspects of Medicine, 2018, 59, 70-84.	2.7	19
57	Intratumor heterogeneity ofHMCN1mutant alleles associated with poor prognosis in patients with breast cancer. Oncotarget, 2018, 9, 33337-33347.	0.8	18
58	Incorporating Genomics Into the Care of Patients With Advanced Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 56-64.	1.8	5
59	Tumor Mutation Burden as a Biomarker in Resected Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2995-3006.	0.8	223
60	The immune system profoundly restricts intratumor genetic heterogeneity. Science Immunology, 2018, 3, .	5.6	83
61	High-resolution deconstruction of evolution induced by chemotherapy treatments in breast cancer xenografts. Scientific Reports, 2018, 8, 17937.	1.6	15
62	Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden. OncoImmunology, 2018, 7, e1526613.	2.1	60
63	The impact of pharmacokinetic gene profiles across human cancers. BMC Cancer, 2018, 18, 577.	1.1	3
64	Distinct subtypes of genomic PTEN deletion size influence the landscape of aneuploidy and outcome in prostate cancer. Molecular Cytogenetics, 2018, 11, 1.	0.4	29
65	Genetic heterogeneity and mutational signature in Chinese Epstein-Barr virus-positive diffuse large B-cell lymphoma. PLoS ONE, 2018, 13, e0201546.	1.1	13
66	Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations. Npj Breast Cancer, 2018, 4, 23.	2.3	26
67	Harnessing Tumor Evolution to Circumvent Resistance. Trends in Genetics, 2018, 34, 639-651.	2.9	49
68	Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy. European Urology Focus, 2019, 5, 416-424.	1.6	20
69	Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 364.	3.5	63
70	PRISM: methylation pattern-based, reference-free inference of subclonal makeup. Bioinformatics, 2019, 35, i520-i529.	1.8	10
71	Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells. Antibodies, 2019, 8, 41.	1.2	90
72	Tumor clonal status predicts clinical outcomes of lung adenocarcinoma with EGFR-TKI sensitizing mutation. Journal of Cancer, 2019, 10, 5549-5556.	1.2	4
73	Assessing reliability of intra-tumor heterogeneity estimates from single sample whole exome sequencing data. PLoS ONE, 2019, 14, e0224143.	1.1	16

#	Article	IF	Citations
74	Single-cell sequencing and its applications in head and neck cancer. Oral Oncology, 2019, 99, 104441.	0.8	65
75	Gain of function in somatic TP53 mutations is associated with immuneâ€rich breast tumors and changes in tumorâ€associated macrophages. Molecular Genetics & Genomic Medicine, 2019, 7, e1001.	0.6	17
76	Triple-Negative Breast Cancer with High Levels of Annexin A1 Expression Is Associated with Mast Cell Infiltration, Inflammation, and Angiogenesis. International Journal of Molecular Sciences, 2019, 20, 4197.	1.8	81
77	Tumor Infiltrating Lymphocytes and Macrophages Improve Survival in Microsatellite Unstable Colorectal Cancer. Scientific Reports, 2019, 9, 13455.	1.6	80
78	The Effects of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancerâ€"The Impact in Intratumoral Heterogeneity. Frontiers in Oncology, 2019, 9, 974.	1.3	20
79	Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities. Genes and Development, 2019, 33, 1295-1318.	2.7	203
80	The evolving role of immunoâ€oncology for the treatment of head and neck cancer. Laryngoscope Investigative Otolaryngology, 2019, 4, 62-69.	0.6	3
81	Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival. International Journal of Molecular Sciences, 2019, 20, 2655.	1.8	59
82	Associating somatic mutations to clinical outcomes: a pan-cancer study of survival time. Genome Medicine, 2019, 11, 37.	3.6	8
83	Genomic pattern of intratumor heterogeneity predicts the risk of progression in early stage diffuse large B-cell lymphoma. Carcinogenesis, 2019, 40, 1427-1434.	1.3	11
84	A Systematic Pan-Cancer Analysis of Genetic Heterogeneity Reveals Associations with Epigenetic Modifiers. Cancers, 2019, 11, 391.	1.7	12
85	Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes. BMC Cancer, 2019, 19, 215.	1.1	10
86	Tumor Heterogeneity as a Predictor of Response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. Clinical Colorectal Cancer, 2019, 18, 102-109.	1.0	25
87	Tumor Heterogeneity Correlates with Less Immune Response and Worse Survival in Breast Cancer Patients. Annals of Surgical Oncology, 2019, 26, 2191-2199.	0.7	127
88	Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women. Breast Cancer Research and Treatment, 2019, 175, 247-259.	1.1	43
89	Tumor diversity and the trade-off between universal cancer tasks. Nature Communications, 2019, 10, 5423.	5.8	53
90	Molecular Characterization of Locally Relapsed Head and Neck Cancer after Concomitant Chemoradiotherapy. Clinical Cancer Research, 2019, 25, 7256-7265.	3.2	18
91	Pathological factors involved in local failure in squamous cell carcinoma of the oral cavity: retrospective study and proposal of a new clinical classification. International Journal of Oral and Maxillofacial Surgery, 2019, 48, 143-151.	0.7	1

#	Article	IF	Citations
92	DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. Clinical Cancer Research, 2019, 25, 641-651.	3.2	21
93	Prognostic impact of intra-field heterogeneity in oral squamous cell carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 585-595.	1.4	17
94	Is high-risk cutaneous squamous cell carcinoma of the head and neck a suitable candidate for current targeted therapies?. Journal of Clinical Pathology, 2020, 73, 17-22.	1.0	6
95	contamDE-lm: linear model-based differential gene expression analysis using next-generation RNA-seq data from contaminated tumor samples. Bioinformatics, 2020, 36, 2492-2499.	1.8	2
96	Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. Oncogene, 2020, 39, 1846-1859.	2.6	29
97	Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome. Nature Communications, 2020, 11, 4995.	5.8	70
98	Increased number of subclones in lung squamous cell carcinoma elicits overexpression of immune related genes. Translational Lung Cancer Research, 2020, 9, 659-669.	1.3	5
99	Lower mutant-allele tumor heterogeneity is a biomarker in FGFR3-mutant bladder cancer for better prognosis. World Journal of Surgical Oncology, 2020, 18, 310.	0.8	6
100	Tumor evolutionary trajectories during the acquisition of invasiveness in early stage lung adenocarcinoma. Nature Communications, 2020, 11, 6083.	5.8	15
101	DNA Methylation-Based Panel Predicts Survival of Patients With Clear Cell Renal Cell Carcinoma and Its Correlations With Genomic Metrics and Tumor Immune Cell Infiltration. Frontiers in Cell and Developmental Biology, 2020, 8, 572628.	1.8	4
102	Molecular margins in head and neck cancer: Current techniques and future directions. Oral Oncology, 2020, 110, 104893.	0.8	13
103	Whole-exome sequencing of long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer. British Journal of Cancer, 2020, 123, 1219-1222.	2.9	4
104	Quantification of cancer driver mutations in human breast and lung <scp>DNA</scp> using targeted, errorâ€corrected <scp>CarcSeq</scp>. Environmental and Molecular Mutagenesis, 2020, 61, 872-889.	0.9	6
105	An algorithm to quantify intratumor heterogeneity based on alterations of gene expression profiles. Communications Biology, 2020, 3, 505.	2.0	50
106	Methodological Advancements for Investigating Intra-tumoral Heterogeneity in Breast Cancer at the Bench and Bedside. Journal of Mammary Gland Biology and Neoplasia, 2020, 25, 289-304.	1.0	6
107	Prognostic significance of mutant-allele tumor heterogeneity in uterine corpus endometrial carcinoma. Annals of Translational Medicine, 2020, 8, 339-339.	0.7	10
108	Clinical relevance of tumor microenvironment: immune cells, vessels, and mouse models. Human Cell, 2020, 33, 930-937.	1.2	53
109	Inter- and intratumor DNA methylation heterogeneity associated with lymph node metastasis and prognosis of esophageal squamous cell carcinoma. Theranostics, 2020, 10, 3035-3048.	4.6	21

#	Article	IF	Citations
110	A DNA Methylation-Based Panel for the Prognosis and Diagnosis of Patients With Breast Cancer and Its Mechanisms. Frontiers in Molecular Biosciences, 2020, 7, 118.	1.6	11
111	Multi-dimensional omics characterization in glioblastoma identifies the purity-associated pattern and prognostic gene signatures. Cancer Cell International, 2020, 20, 37.	1.8	14
112	Biologically Aggressive Phenotype and Anti-cancer Immunity Counterbalance in Breast Cancer with High Mutation Rate. Scientific Reports, 2020, 10, 1852.	1.6	65
113	Passenger Mutations in More Than 2,500 Cancer Genomes: Overall Molecular Functional Impact and Consequences. Cell, 2020, 180, 915-927.e16.	13.5	98
114	Intratumor heterogeneity could inform the use and type of postoperative adjuvant therapy in patients with head and neck squamous cell carcinoma. Cancer, 2020, 126, 1895-1904.	2.0	11
115	p53 functional states are associated with distinct aldehyde dehydrogenase transcriptomic signatures. Scientific Reports, 2020, 10, 1097.	1.6	5
116	Clinical implications of intratumor heterogeneity: challenges and opportunities. Journal of Molecular Medicine, 2020, 98, 161-177.	1.7	241
117	Comparative bioinformatical analysis of pancreatic head cancer and pancreatic body/tail cancer. Medical Oncology, 2020, 37, 46.	1.2	20
118	Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2020, 26, 1474-1485.	3.2	62
119	Multiomics data reveals the influences of myasthenia gravis on thymoma and its precision treatment. Journal of Cellular Physiology, 2021, 236, 1214-1227.	2.0	6
120	Full-coverage TP53 deep sequencing of recurrent head and neck squamous cell carcinoma facilitates prognostic assessment after recurrence. Oral Oncology, 2021, 113, 105091.	0.8	7
121	Dynamic analysis of circulating tumor <scp>DNA</scp> to predict prognosis and monitor therapeutic response in metastatic relapsed cervical cancer. International Journal of Cancer, 2021, 148, 921-931.	2.3	13
122	Towards multi-omics characterization of tumor heterogeneity: a comprehensive review of statistical and machine learning approaches. Briefings in Bioinformatics, 2021, 22, .	3.2	19
123	Impact of 18F-FDG PET, PET/CT, and PET/MRI on Staging and Management as an Initial Staging Modality in Breast Cancer. Clinical Nuclear Medicine, 2021, 46, 271-282.	0.7	45
124	Neoantigen landscape in metastatic nasopharyngeal carcinoma. Theranostics, 2021, 11, 6427-6444.	4.6	14
125	Molecular correlates of immune cytolytic subgroups in colorectal cancer by integrated genomics analysis. NAR Cancer, 2021, 3, zcab005.	1.6	9
126	Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients. Nature Communications, 2021, 12, 11.	5.8	121
127	DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis. Annals of Translational Medicine, 2021, 9, 220-220.	0.7	11

#	Article	IF	Citations
128	Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 786-793.	2.0	4
129	Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer. Molecular Cancer, 2021, 20, 37.	7.9	36
131	Clinicopathological characteristics of primary peritoneal epithelioid mesothelioma of clear cell type. Medicine (United States), 2021, 100, e25264.	0.4	2
132	Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response. Nature Communications, 2021, 12, 1998.	5.8	37
133	Single-Cell Deconvolution of Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 1230.	1.7	26
134	Plasma cell marker, immunoglobulin J polypeptide, predicts early disease-specific mortality in HPV+ HNSCC. , 2021, 9, e001259.		9
135	Prognosis and Genomic Landscape of Liver Metastasis in Patients With Breast Cancer. Frontiers in Oncology, 2021, 11, 588136.	1.3	10
136	A Comprehensive Investigation to Reveal the Relationship Between Plasmacytoid Dendritic Cells and Breast Cancer by Multiomics Data Analysis. Frontiers in Cell and Developmental Biology, 2021, 9, 640476.	1.8	10
137	Group Behavior and Emergence of Cancer Drug Resistance. Trends in Cancer, 2021, 7, 323-334.	3.8	21
138	Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell, 2021, 184, 2239-2254.e39.	13.5	260
139	Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 646874.	2.2	6
140	CarcSeq Measurement of Rat Mammary Cancer Driver Mutations and Relation to Spontaneous Mammary Neoplasia. Toxicological Sciences, 2021, 182, 142-158.	1.4	3
141	Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers. Genome Medicine, 2021, 13, 70.	3.6	8
142	Intra-Tumoral Genomic Heterogeneity in Rectal Cancer: Mutational Status Is Dependent on Preoperative Biopsy Depth and Location. Cancers, 2021, 13, 2271.	1.7	4
143	Copy number signature analysis tool and its application in prostate cancer reveals distinct mutational processes and clinical outcomes. PLoS Genetics, 2021, 17, e1009557.	1.5	65
144	Chromosomal copy number heterogeneity predicts survival rates across cancers. Nature Communications, 2021, 12, 3188.	5.8	43
145	MesKit: a tool kit for dissecting cancer evolution of multi-region tumor biopsies through somatic alterations. GigaScience, 2021, 10, .	3.3	13
146	MicroRNA as a Novel Biomarker in the Diagnosis of Head and Neck Cancer. Biomolecules, 2021, 11, 844.	1.8	26

#	Article	IF	Citations
147	Correlation Between the Evolution of Somatic Alterations During Lymphatic Metastasis and Clinical Outcome in Penile Squamous Cell Carcinoma. Frontiers in Oncology, 2021, 11, 641869.	1.3	0
148	Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification. Npj Precision Oncology, 2021, 5, 47.	2.3	10
149	DITHER: an algorithm for Defining IntraTumor Heterogeneity based on EntRopy. Briefings in Bioinformatics, 2021, 22, .	3.2	16
150	Epithelialâ€“Mesenchymal Transition Associated with Head and Neck Squamous Cell Carcinomas: A Review. Cancers, 2021, 13, 3027.	1.7	18
151	Identification of gastric cancer subtypes based on pathway clustering. Npj Precision Oncology, 2021, 5, 46.	2.3	28
152	Octogenariansâ€™ Breast Cancer Is Associated with an Unfavorable Tumor Immune Microenvironment and Worse Disease-Free Survival. Cancers, 2021, 13, 2933.	1.7	4
153	Risk Signature of Cancer-Associated Fibroblastâ€“Secreted Cytokines Associates With Clinical Outcomes of Breast Cancer. Frontiers in Oncology, 2021, 11, 628677.	1.3	9
155	Development and validation of an intra-tumor heterogeneity-related signature to predict prognosis of bladder cancer: a study based on single-cell RNA-seq. Aging, 2021, 13, 19415-19441.	1.4	7
156	Assessing tumor heterogeneity: integrating tissue and circulating tumor DNA (ctDNA) analysis in the era of immuno-oncology - blood TMB is not the same as tissue TMB. , 2021, 9, e002551.		19
157	Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types. JCO Precision Oncology, 2021, 5, 1270-1280.	1.5	9
158	Genetic and immune characteristics of multiple primary lung cancers and lung metastases. Thoracic Cancer, 2021, 12, 2544-2550.	0.8	5
159	DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer. Frontiers in Oncology, 2021, 11, 708294.	1.3	15
161	A combination of intra-tumor genetic heterogeneity, estrogen receptor alpha and human papillomavirus status predicts outcomes in head and neck squamous cell carcinoma following chemoradiotherapy. Oral Oncology, 2021, 120, 105421.	0.8	5
162	DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation. Nature Communications, 2021, 12, 5406.	5.8	29
163	The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome Sequencing. Journal of Clinical Medicine, 2021, 10, 215.	1.0	5
165	The Genome-Wide Molecular Landscape of HPV-Driven and HPV-Negative Head and Neck Squamous Cell Carcinoma. Current Cancer Research, 2018, , 293-325.	0.2	4
166	Role of the NOTCH Signaling Pathway in Head and Neck Cancer. Current Cancer Research, 2018, , 229-248.	0.2	4
167	Genomic landscape of lung adenocarcinoma in East Asians. Nature Genetics, 2020, 52, 177-186.	9.4	281

#	Article	IF	Citations
173	Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097711.	1.4	20
174	Pan-cancer analysis of intratumor heterogeneity associated with patient prognosis using multidimensional measures. Oncotarget, 2018, 9, 37689-37699.	0.8	7
175	Clinical relevance of mutant-allele tumor heterogeneity and lung adenocarcinoma. Annals of Translational Medicine, 2019, 7, 432-432.	0.7	18
176	Mutantâ€allele tumor heterogeneity in malignant glioma effectively predicts neoplastic recurrence. Oncology Letters, 2019, 18, 6108-6116.	0.8	5
177	MYTH: An algorithm to score intratumour heterogeneity based on alterations of DNA methylation profiles. Clinical and Translational Medicine, 2021, 11, e611.	1.7	3
178	Genetics and Epigenetics of Head and Neck Cancer. , 2016, , 115-132.		0
180	Ideafix: a decision tree-based method for the refinement of variants in FFPE DNA sequencing data. NAR Genomics and Bioinformatics, 2021, 3, lqab092.	1.5	2
181	PRCC reduces the sensitivity of cancer cells to DNA damage by inhibiting JNK and ATM/ATR pathways and results in a poor prognosis in hepatocellular carcinoma. Cell and Bioscience, 2021, 11, 185.	2.1	0
183	Intra-tumoral heterogeneity and immune responses predicts prognosis of gastric cancer. Aging, 2020, 12, 24333-24344.	1.4	7
184	The modulation relationship of genomic pattern of intratumor heterogeneity and immunity microenvironment heterogeneity in hepatocellular carcinoma. Oncology Letters, 2020, 20, 233.	0.8	0
185	Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer. American Journal of Cancer Research, 2021, 11, 3628-3644.	1.4	3
186	The modulation relationship of genomic pattern of intratumor heterogeneity and immunity microenvironment heterogeneity in hepatocellular carcinoma. Oncology Letters, 2020, 20, 1-1.	0.8	2
187	Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine. Drug Resistance Updates, 2022, 60, 100806.	6.5	41
188	Comprehensive Comparative Molecular Characterization of Young and Old Lung Cancer Patients. Frontiers in Oncology, 2021, 11, 806845.	1.3	6
189	Neoantigens and the tumor microenvironment play important roles in the prognosis of high-grade serous ovarian cancer. Journal of Ovarian Research, 2022, 15, 18.	1.3	7
190	Somatic mutation analyses of stem-like cells in gingivobuccal oral squamous cell carcinoma reveals DNA damage response genes. Genomics, 2022, 114, 110308.	1.3	1
191	Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nature Communications, 2021, 12, 7338.	5.8	104
192	Machine learning radiomics can predict early liver recurrence after resection of intrahepatic cholangiocarcinoma. Hpb, 2022, 24, 1341-1350.	0.1	7

#	Article	IF	Citations
193	PTEN Loss and BRCA1 Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer. JCO Precision Oncology, 2022, 6, e2100159.	1.5	4
195	DEPTH2: an mRNA-based algorithm to evaluate intratumor heterogeneity without reference to normal controls. Journal of Translational Medicine, 2022, 20, 150.	1.8	8
196	Disparate genomic characteristics of patients with early-stage lung adenocarcinoma manifesting as radiological subsolid or solid lesions. Lung Cancer, 2022, 166, 178-188.	0.9	5
197	Genomic clonal evolution correlated with phenotype and prognosis in gastric cancer. Clinical and Translational Medicine, 2022, 12, e799.	1.7	0
198	Therapy-Related Transcriptional Subtypes in Matched Primary and Recurrent Head and Neck Cancer. Clinical Cancer Research, 2022, 28, 1038-1052.	3.2	13
199	Quantification of tumor heterogeneity: from data acquisition to metric generation. Trends in Biotechnology, 2022, 40, 647-676.	4.9	29
200	A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosity. Nature Communications, 2022, 13, 1925.	5.8	8
201	Comparative Genomic Analysis Reveals Genetic Variations in Multiple Primary Esophageal Squamous Cell Carcinoma of Chinese Population. Frontiers in Oncology, 2022, 12, 868301.	1.3	3
212	Plasma-Based Measurements of Tumor Heterogeneity Correlate with Clinical Outcomes in Metastatic Colorectal Cancer. Cancers, 2022, 14, 2240.	1.7	1
213	Functionalized Lineage Tracing Can Enable the Development of Homogenization-Based Therapeutic Strategies in Cancer. Frontiers in Immunology, 2022, 13, .	2.2	1
214	Kidney Cancer Models for Pre-Clinical Drug Discovery: Challenges and Opportunities. Frontiers in Oncology, 2022, 12, .	1.3	2
215	Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types. JCO Precision Oncology, 2022, , .	1.5	18
216	Impact of Region-of-Interest Size on Immune Profiling Using Multiplex Immunofluorescence Tyramide Signal Amplification for Paraffin-Embedded Tumor Tissues. Pathobiology, 2023, 90, 1-12.	1.9	5
217	Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles. Journal of Investigative Dermatology, 2022, 142, 3030-3040.e5.	0.3	6
218	Stepwise evolutionary genomics of early-stage lung adenocarcinoma manifesting as pure, heterogeneous and part-solid ground-glass nodules. British Journal of Cancer, 2022, 127, 747-756.	2.9	4
220	Multi-Omics Integrative Analysis of Lung Adenocarcinoma: An in silico Profiling for Precise Medicine. Frontiers in Medicine, 0, 9, .	1.2	4
221	Contribution and clinical relevance of germline variation to the cancer transcriptome. BMC Cancer, 2022, 22, .	1.1	0
222	Prognostic Characteristics of Immune-Related Genes and the Related Regulatory Axis in Patients With Stage N+M0 Breast Cancer. Frontiers in Oncology, 0, 12, .	1.3	0

#	Article	IF	Citations
223	Whole-Exome Sequencing Uncovers Specific Genetic Variation Difference Based on Different Modes of Drug Resistance in Small Cell Lung Cancer. Frontiers in Oncology, 0, 12, .	1.3	0
224	An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma. Frontiers in Medicine, 0, 9, .	1.2	0
225	Differential Infiltration of Immune Cells Driven by Tumor Heterogeneity Reveals Two Immune Subtypes in Lung Adenocarcinoma. Frontiers in Genetics, 0, 13, .	1.1	0
226	Mutant-Allele Tumor Heterogeneity, a Favorable Biomarker to Assess Intra-Tumor Heterogeneity, in Advanced Lung Adenocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	4
227	Applications of singleâ€cell multiâ€omics sequencing in deep understanding of brain diseases. Clinical and Translational Discovery, 2022, 2, .	0.2	0
228	Evolution of intra-tumoral heterogeneity across different pathological stages in papillary thyroid carcinoma. Cancer Cell International, 2022, 22, .	1.8	7
229	Comprehensive analyses unveil novel genomic and immunological characteristics of micropapillary pattern in lung adenocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	4
230	Whole-Exome Sequencing Reveals the Genomic Features of the Micropapillary Component in Ground-Glass Opacities. Cancers, 2022, 14, 4165.	1.7	3
231	Dualistic classification of high grade serous ovarian carcinoma has its root in spatial heterogeneity. Journal of Advanced Research, 2022, , .	4.4	1
232	Pyroptosis: a novel signature to predict prognosis and immunotherapy response in gliomas. Human Cell, 2022, 35, 1976-1992.	1.2	2
233	Clonal evolution characteristics and reduced dimension prognostic model for non-metastatic metachronous bilateral breast cancer. Frontiers in Oncology, 0, 12, .	1.3	0
234	Comparative analysis of capture methods for genomic profiling of circulating tumor cells in colorectal cancer. Genomics, 2022, 114, 110500.	1.3	2
235	Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodules. British Journal of Cancer, 0, , .	2.9	0
236	Chromosomal Instability, Selection and Competition: Factors That Shape the Level of Karyotype Intra-Tumor Heterogeneity. Cancers, 2022, 14, 4986.	1.7	8
237	Preliminary study on the molecular features of mutation in multiple primary oral cancer by whole exome sequencing. Frontiers in Oncology, 0, 12, .	1.3	3
239	Deep learning image analysis quantifies tumor heterogeneity and identifies microsatellite instability in colon cancer. Journal of Surgical Oncology, 2023, 127, 426-433.	0.8	3
240	Systematic pan-cancer analysis showed that RAD51AP1 was associated with immune microenvironment, tumor stemness, and prognosis. Frontiers in Genetics, 0, 13, .	1.1	3
241	Integrated Multi-Omics Landscape of Liver Metastases. Gastroenterology, 2023, 164, 407-423.e17.	0.6	17

#	Article	IF	Citations
242	A pan-cancer analysis of the oncogenic role of zinc finger protein 419 in human cancer. Frontiers in Oncology, 0, 12, .	1.3	6
243	Integrated analysis of racial disparities in genomic architecture identifies a transâ€ancestry prognostic subtype in bladder cancer. Molecular Oncology, 2023, 17, 564-581.	2.1	0
245	Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer. Nature Communications, 2022, 13, .	5.8	12
246	Multi-region sequencing with spatial information enables accurate heterogeneity estimation and risk stratification in liver cancer. Genome Medicine, 2022, 14, .	3.6	10
247	Exploring biomarkers for prognosis and neoadjuvant chemosensitivity in rectal cancer: Multi-omics and ctDNA sequencing collaboration. Frontiers in Immunology, 0, 13, .	2.2	2
248	DEF6 has potential to be a biomarker for cancer prognosis: A pan-cancer analysis. Frontiers in Oncology, 0, 12, .	1.3	0
249	Identification of the ageingâ€related prognostic gene signature, and the associated regulation axis in skin cutaneous melanoma. Scientific Reports, 2023, 13, .	1.6	0
250	A lipid metabolismâ€“based prognostic risk model for HBVâ€“related hepatocellular carcinoma. Lipids in Health and Disease, 2023, 22, .	1.2	1
251	Analysis on methylation and expression of PSMB8 and its correlation with immunity and immunotherapy in lung adenocarcinoma. Epigenomics, 2022, 14, 1427-1448.	1.0	0
252	Evolutionary route of nasopharyngeal carcinoma metastasis and its clinical significance. Nature Communications, 2023, 14, .	5.8	5
253	Patient-derived three-dimensional culture techniques model tumor heterogeneity in head and neck cancer. Oral Oncology, 2023, 138, 106330.	0.8	2
254	An Integrative Analysis of Nasopharyngeal Carcinoma Genomes Unraveled Unique Processes Driving a Viral-Positive Cancer. Cancers, 2023, 15, 1243.	1.7	0
255	Differences between Squamous Cell Carcinomas of the Base of the Tongue and the Tonsils in Prevalence of HPV16 Infection, Its Type, and Clinical Features. Journal of Personalized Medicine, 2023, 13, 361.	1.1	0
256	A novel prognostic scoring model based on copper homeostasis and cuproptosis which indicates changes in tumor microenvironment and affects treatment response. Frontiers in Pharmacology, 0, 14, .	1.6	3
257	Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade. Journal of Clinical Oncology, 2023, 41, 3225-3235.	0.8	4
258	Pan-Cancer analysis and experimental validation identify the oncogenic nature of ESPL1: Potential therapeutic target in colorectal cancer. Frontiers in Immunology, 0, 14, .	2.2	0
259	Identification of HPV16 E1 and E2-specific T cells in the oropharyngeal cancer tumor microenvironment. , 2023, 11, e006721.		3
260	A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma. Frontiers in Immunology, 0, 14, .	2.2	3

#	Article	IF	Citations
262	Clinicopathologic Features and Genetic Alterations in Mixed-Type Ampullary Carcinoma. Modern Pathology, 2023, 36, 100181.	2.9	1
263	Defining multiple layers of intratumor heterogeneity based on variations of perturbations in multi-omics profiling. Computers in Biology and Medicine, 2023, , 106964.	3.9	1
264	Inferring early genetic progression in cancers with unobtainable premalignant disease. Nature Cancer, 2023, 4, 550-563.	5.7	10
265	bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer. EBioMedicine, 2023, 91, 104564.	2.7	1
292	Quantifying Intratumor Heterogeneity by Key Genes Selected Using Concrete Autoencoder. Lecture Notes in Computer Science, 2023, , 844-852.	1.0	1
305	Cancer Stem Cells: Current Challenges and Future Perspectives. Methods in Molecular Biology, 2024, , 1-18.	0.4	0